CLYM – climb bio, inc. (US:NASDAQ)

News

Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway [Seeking Alpha]
Climb Bio (CLYM) was upgraded by Mizuho to "strong-buy".
Climb Bio (CLYM) was given a new $18.00 price target by Mizuho.
Climb Bio (CLYM) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com